Tauriga Sciences, trading under the symbol TAUG on the OTCMKTS, is a life sciences commercialization company focused on advancing early-stage therapeutic and diagnostic assets. Through strategic investments, licensing agreements and joint ventures, the company seeks to bridge the gap between innovative research and market-ready products. Its core areas of interest include women’s health solutions, novel delivery systems and psychedelic-assisted therapies aimed at addressing unmet medical needs.
The company’s portfolio spans from botanical extraction and formulation technologies to digital health platforms. In women’s health, Tauriga Sciences is developing nonhormonal treatments for menopausal symptoms and chronic pelvic pain, leveraging proprietary extraction methods to isolate active compounds. On the psychedelics front, the firm explores microdosing regimens of psilocybin and related compounds to support mental health interventions, collaborating with academic institutions to conduct early-phase clinical evaluations. Complementary services include analytical testing and contract manufacturing, providing end-to-end support for natural product development.
Originally incorporated in Canada, Tauriga Sciences has expanded its reach with operations and partnerships in the United States and Europe. The company’s growth strategy emphasizes geographic diversification and regulatory alignment, securing manufacturing facilities in North America while navigating evolving frameworks for psychedelic research. By engaging with leading universities and regulatory bodies, Tauriga aims to expedite the translation of promising molecules into approved therapies.
Leadership at Tauriga Sciences brings together seasoned executives and scientific experts. Chief Executive Officer Scott Durner has over two decades of experience in life sciences commercialization, while Chief Scientific Officer Dr. Sarah Livingston has led multiple clinical-stage programs in women’s health. Supported by a board of directors with backgrounds in pharma, finance and biotech innovation, the management team is positioned to advance the company’s pipeline and pursue strategic collaborations that enhance shareholder value.
AI Generated. May Contain Errors.
